We recently reported that neuropilin 1 (NRP1) drives angiogenesis by promoting extracellular matrix signaling in endothelial cells via ABL1 kinase. Imatinib targets this pathway in pathological angiogenesis and may provide a novel opportunity for anti-angiogenic therapy of age-related macular degeneration, proliferative diabetic retinopathy, or solid tumor growth.
Imatinib may be ABL to improve anti-angiogenic therapy / C. Raimondi, A. Fantin, C. Ruhrberg. - In: MOLECULAR & CELLULAR ONCOLOGY. - ISSN 2372-3556. - 2:1(2015), pp. e968034.1-e968034.3. [10.4161/23723548.2014.968034]
Imatinib may be ABL to improve anti-angiogenic therapy
A. FantinSecondo
;
2015
Abstract
We recently reported that neuropilin 1 (NRP1) drives angiogenesis by promoting extracellular matrix signaling in endothelial cells via ABL1 kinase. Imatinib targets this pathway in pathological angiogenesis and may provide a novel opportunity for anti-angiogenic therapy of age-related macular degeneration, proliferative diabetic retinopathy, or solid tumor growth.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Imatinib may be ABL to improve anti angiogenic therapy.pdf
accesso aperto
Descrizione: Note
Tipologia:
Publisher's version/PDF
Dimensione
1.68 MB
Formato
Adobe PDF
|
1.68 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
